Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nateglinide in renal transplant recipients with post-transplant diabetes
NCT00319189Phase 4Completed
- Sponsor
- University of Oslo School of Pharmacy
- Start
- Nov 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nateglinide in diabetes mellitus (DM) and impaired glucose tolerance (IGT), sponsored by University of Oslo School of Pharmacy. Primary endpoints: Glucose tolerance at 2 weeks and Insulin release at 2 weeks. Started Nov 2002; status: completed.
02
Drugs
nateglinide
03
Conditions
diabetes mellitus (DM)impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT00319189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319189.